Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL).

ABSTRACT: Acute lymphoblastic leukemia (ALL) is a rare hematological malignancy characterized by proliferation and accumulation of premature lymphoid blasts. Depending on risk factors, the survival of acute lymphoblastic leukemia has significantly improved over the last decades. During the last years, measurable residual disease (MRD) assessment has evolved into one of the most sensitive markers for prognosis and risk of relapse. For this reason, measurable residual disease detection and monitoring count as standard evaluation in patients with acute lymphoblastic leukemia. Allogeneic stem cell transplantation is still the recommended treatment option for patients with high and highest risk profiles as well as for relapsed or refractory settings. The increased understanding of the pathomechanism and

SUBMITTER: Kunz T 

PROVIDER: S-EPMC9454969 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature